Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8189102 | 0.82 | SMN1; SMN2 (0.47) | CYP2A6NPC1RAB9ASMN1; SMN2HDAC3 | |
| SCHEMBL3597089 | 0.81 | HSD17B10 (0.50) | CYP2A6CA12CA2CA3CA4 | |
| SCHEMBL24297526 | 0.78 | ESR1 (0.38) | NPC1RAB9ASMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL19756719 | 0.78 | CA2 (0.44) | CA2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8221541 | 0.78 | GABRA1 (0.41) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL422041 | 0.77 | HDAC3 (0.52) | CYP2A6NPC1RAB9AHDAC3HDAC4 | |
| SCHEMBL12278184 | 0.74 | CA2 (0.52) | CA1CA2CA4NPC1RAB9A | |
| SCHEMBL1888634 | 0.72 | PTPN2 (0.47) | NPC1RAB9ASMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL18949250 | 0.72 | PTGS1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6232099 | 0.71 | CYP2A6 (0.59) | CYP2A6ROCK1ASIC3LOXL2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| EP-2134713-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008082490-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | CYP2A6 1718/4885ROCK1 868/4885ASIC3 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.